title: [Anti-HIV drugs].
abstract: Anti-HIV drugs are fall into the following 5 categories: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and C-C chemokine receptor type 5 (CCR5) inhibitors. An appropriate combination of anti-HIV drugs, which is called ART (anti-retroviral therapy), can suppress HIV replication for prolonged periods. Since many anti-HIV drugs with relatively few side effects as well as high-potency have been developed recently, early initiation of ART is recommended regardless of the patients' CD4+ T-cell counts. However, ART does not lead to eradication or cure of HIV because of latent infection. Interruption of ART leads to a rapid rebound of viremia, necessitating life-long treatment. Thus, strategies to eradicate HIV from latently infected cells are urgently needed.
authors.affiliation: Department of Infectious Diseases and Applied Immunology IMSUT Hospital, The Institute of Medical Science, The University of Tokyo.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Koibuchi
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000145:classification / Q000494:pharmacology; D065100:CCR5 Receptor Antagonists; D004359:Drug Therapy, Combination; D006678:HIV / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D019428:HIV Integrase Inhibitors; D006801:Humans; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D017735:Virus Latency; D014779:Virus Replication / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D019428:HIV Integrase Inhibitors; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors